Abstract
Intravenous immunoglobulin (IVIg) is a safe preparation made from human plasma. The original concept of IVIg as an anticancer drug was built up over the years, after numeral reports were accumulated indicating cancer regressions after IVIg administration. Because IVIg is basically an established remedy for immunodeficiencies and several autoimmune diseases, the association between beneficial effects in cancer patients after IVIg was first seen in patients who had both cancer and autoimmune or immunodeficiency diseases.
Interestingly, cancer and autoimmunity share several common features, which together enhance the notion of using IVIg to treat cancer.
Several studies tested the broad range of the antimetastatic effects of IVIg. IVIg was found to operate in many different and complex ways, among them (a) induction of interleukin-12 secretion, leading to natural-killer-cell activation; (b) inhibition of matrix metalloproteinase-9 mRNA expression; (c) suppression of tumor cell growth; (d) hindrance of nuclear factor κB activation and IκB degradation; and (e) G1 cell-cycle arrest.
In conclusion, IVIg is a potential anticancer treatment for several reasons: (a) the bidirectional relationship between cancer and autoimmunity; (b) the apparent association between cancer regression and IVIg administration; (c) a variety of anticancer effects of IVIg observed; and (d) IVIg is considered to be a safe preparation with minimal side effects. Obviously, prospective controlled studies that will establish the antitumor effects of IVIg are needed.
Similar content being viewed by others
References
Fishman, P., Bar-Yehuda, S., and Shoenfeld, Y. (2002), Int J Oncol 21, 875–880.
Kazatchkine, M. D. and Kaveri, S. V. (2001), N Engl J Med 345, 747–755.
Marinos, C., Dalakas, M. C., and Spath, P. J. In: Marinos, C., Dalakas, M. C., Spath, P. J., eds. Intravenous Immunoglobulins in the Third Millennium. New York/London: Parthenon Publishing Group, 2004, pp. 1–409.
Segal, E. and Shoenfeld, Y. (2001), Harefuah 140, 955–958.
Dalakas, M. C. (1997), Ann Intern Med 126, 721–730.
Shoenfeld, Y. and Fishman, P. (1999), Int Immunol. 11, 1247–1252.
Tomer, Y. and Shoenfeld, Y. In: Shoenfeld, Y., Gershwin, E. M., eds. Cancer and Autoimmunity. Amsterdam: Elsevier, 2000, pp. 141–150.
Tishler, M. and Shoenfeld, Y. In: Shoenfeld, Y., Gershwin, E. M., eds. Cancer and Autoimmunity. Amsterdam: Elsevier, 2000, pp. 121–132.
Sherer, Y. and Shoenfeld, Y. In: Shoenfeld, Y., Gershwin, E. M., eds. Cancer and Autoimmunity. Amsterdam: Elsevier, 2000, pp. 249–252.
Huminer, D., Tomer, Y., Pitlick, S., and Shoenfeld, Y. (1991), Autoimmunity 5, 232–233.
Swissa, M., Cohen, Y., and Shoenfeld, Y. (1990), Cancer 65, 2554–2558.
Shoenfeld, Y. and Isenberg, D. A. (1989), Immunol Today 10, 123–126.
Shoenfeld, Y., Kennedy, R., Ferrano, S., eds. (1997), Idiotypes in Autoimmunity, Infectious Diseases and Cancer. Amsterdam: Elsevier.
Shapiro, S., Shoenfeld, Y., Gilburd, B., Sobel, E., and Lahat, N. (2002), Cancer 95, 2032–2037.
Vassilev, T. L., Kazatchkine, M. D., Van Huyen, J. P., et al. (1999), Blood 93, 3624–3631.
Ichiyama, T., Ueno, Y., Isumi, H., Niimi, A., Matsubara, T., and Furukawa, S. (2004), Inflamm Res 53, 253–256.
Ekberg, C., Nordstrom, E., Skansen-Saphir, U., et al. (2001), Hum Immunol. 62, 215–227.
Besa, E. C. (1984), Am J Med 76, 209–218.
Carmeli, Y., Mevorach, D., Kaminski, N., Raz, E. (1994), Cancer 73, 2859–2861.
Shoenfeld, Y., Levy, Y., and Fishman, P. (2001), IMAJ 3, 698–699.
Merimsky, O., Meller, I., Inbar, M., Bar-Yehuda, S., Shoenfeld, Y., and Fishman, P. (2002), Int J Oncol. 20, 839–843.
Sipak-Szmigiel, O., Ronin-Walknowska, E., and Miklaszwicz, A. (2003), Ginekol Pol 74, 350–355.
US Patent no. 5,562,902. (1996), Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin.
US Patent no 5,965,130. (1999), Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin.
Bar-Dayan, Y., Barshack, I., Blank, M., et al. (1999), Int J Oncol. 15, 1091–1096.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sapir, T., Shoenfeld, Y. Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy. Clinic Rev Allerg Immunol 29, 307–310 (2005). https://doi.org/10.1385/CRIAI:29:3:307
Issue Date:
DOI: https://doi.org/10.1385/CRIAI:29:3:307